A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY CLINICAL ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST) ADMINISTERED ORALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH HEPATIC METASTASES
- Registry ID
- WP41377
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Last update
- 2021-07-07
Conditions
- METASTATIC COLORECTAL CANCER
- HEPATOCELLULAR CARCINOMA
- BILIARY CANCER
Related clinical trials
- A RANDOMIZED, DOUBLE BLIND, PHASE 3 STUDY OF STANDARD-OF-CARE CHEMOTHERAPY AND BEVACIZUMAB WITH OR WITHOUT INCA33890 IN THE FIRST LINE TREATMENT OF METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER
- AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
- ROSETTA CRC-203: A BLINDED, RANDOMIZED PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, UNRESECTABLE, OR METASTATIC COLORECTAL CANCER
- A RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 3 CLINICAL FOLFOX VERSUS BEVACIZUMAB IN COMBINATION WITH FOLFOX FOR THE FIRST-LINE STUDY OFLVONESCIMAB IN COMBINATION WITH TREATMENT OF METASTATIC COLORECTAL CANCER
- PHASE III, RANDOMIZED, OPEN-LABEL, GLOBAL, MULTICENTER STUDY OF RILVEGOSTOMIG OR DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (ARTEMIDE-BILIARY02)
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY TO EVALUATE
THE SAFETY AND EFFICACY OF MK-1084, CETUXIMAB, AND MFOLFOX6 VERSUS
MFOLFOX6 WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE TREATMENT OF
PARTICIPANTS WITH KRAS G12C-MUTANT, LOCALLY ADVANCED UNRESECTABLE OR
METASTATIC COLORECTAL CANCER (KANDLELIT-012)
View on source registry